In addition to being aberrantly activated in cancer cells, NF-κB is activated by most modalities of cancer therapy [85–87], and aberrant activation of NF-κB is proposed as a major factor contributing to the resistance to chemotherapy. The gene discussed is NFKB1; the disease is cancer.